C3742

Chk2 Inhibitor II hydrate

≥98% (HPLC)

• Sinónimos: 2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide hydrate
• Fórmula empírica (notación de Hill): C₂₀H₁₄ClN₃O₂ · xH₂O
• Número de CAS: 516480-79-8
• Peso molecular: 363.80 (anhydrous basis)
• MDL number: MFCD08276917
• UNSPSC Code: 12352200
• PubChem Substance ID: 24724438
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: solid
• color: off-white to tan
• solubility: DMSO: ≥2 mg/mL (warmed)
• originator: Johnson & Johnson
• storage temp.: 2-8°C
• SMILES string: O=C(C1=CC=C2C(N=C(C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)N2)=C1)N
• InChI: 1S/C20H14ClN3O2/c21-14-4-8-16(9-5-14)26-15-6-1-12(2-7-15)20-23-17-10-3-13(19(22)25)11-18(17)24-20/h1-11H,(H2,22,25)(H,23,24)
• InChI key: UXGJAOIJSROTTN-UHFFFAOYSA-N
• Gene Information: human ... CHEK2(11200)

Descripción

Biochem/physiol Actions

Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer. IC₅₀ = 15 nM; K_i = 37 nM. Chk2 Inhibitor II shows 1000-fold greater selectivity for the Chk2 serine/threonine kinase than for the Cdk1/B and CK1 kinases (for which IC₅₀ = 12 μM and 17 μM, respectively). Chk2 Inhibitor II weakly inhibits a panel of 31 other kinases (<25% inhibition at a concentration of 10 μM and prevents apoptosis of human CD4+ and CD8+ T-cells subjected to ionizing radiation (EC₅₀ = 3 μM and 7.6 μM, respectively).

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable